Clinical Trials on Metastatic Hormone Refractory Prostate Cancer
Total 17135 results
-
Sandy SrinivasWyeth is now a wholly owned subsidiary of Pfizer; American Society of Clinical... and other collaboratorsTerminatedProstatic Neoplasms | Prostate Cancer | Metastatic Disease | Hormone-refractory Prostate Cancer | Castrate-resistant Prostate Cancer (CRPC) | Androgen-insensitive Prostate CancerUnited States
-
Jiangsu HengRui Medicine Co., Ltd.UnknownHormone Refractory Prostate Cancer | Metastatic Prostate CarcinomaChina
-
DendreonCompletedHormone Refractory Prostate Cancer | Castration-resistant Prostate Cancer | Prostate Cancer MetastaticUnited States
-
Stanford UniversityTerminatedProstatic Neoplasms | Prostate Cancer | Metastatic Disease | Hormone-refractory Prostate Cancer | Castrate-resistant Prostate Cancer (CRPC) | Androgen-insensitive Prostate CancerUnited States
-
Duke UniversityUnited States Department of DefenseCompletedMetastatic Hormone Refractory Prostate CancerUnited States
-
Nerviano Medical SciencesCompletedMetastatic Hormone Refractory Prostate CancerItaly
-
Novartis PharmaceuticalsCompletedMetastatic Hormone Refractory Prostate CancerUnited States, France, Spain, Belgium, Singapore, Italy, Australia, Germany
-
SanofiGenzyme, a Sanofi CompanyCompletedProstate Cancer | Metastatic | Hormone RefractoryBrazil, South Africa, Sweden, Germany, Hungary
-
GenesisCare USADendreonCompletedCastrate Refractory Metastatic Prostate Cancer (mCRPC)United States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bayer; Janssen, LP; Prostate Cancer Clinical Trials ConsortiumCompletedStage IV Prostate Adenocarcinoma | Hormone-refractory Prostate Cancer | Prostate Carcinoma Metastatic to the BoneUnited States
-
University of California, IrvineBristol-Myers SquibbCompletedRecurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Hormone-refractory Prostate CancerUnited States
-
Washington University School of MedicineBristol-Myers Squibb; ExelixisActive, not recruitingMetastatic Hormone Refractory Prostate CancerUnited States
-
AmgenCompletedHormone Refractory Prostate Cancer
-
BayerCompletedBone Metastases | Hormone Refractory Prostate CancerItaly, Spain, Hong Kong, Canada, United Kingdom, France, Australia, United States, Germany, Brazil, Israel, Netherlands, Norway, Belgium, Sweden, Czech Republic, Poland, Singapore, Slovakia
-
Northwestern UniversityRecruitingMetastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Refractory Prostate Cancer | Castration-Resistant Prostatic CancerUnited States
-
PfizerAstellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedProstate Cancer | Hormone Refractory Prostate CancerUnited States
-
Spanish Oncology Genito-Urinary GroupAstellas Pharma Inc; Apices Soluciones S.L.CompletedHormone-refractory Prostate CancerSpain
-
Peking UniversityWithdrawnHormone Refractory Prostate CancerChina
-
Tianjin Medical University Cancer Institute and...UnknownHormone Refractory Prostate CancerChina
-
CytoVac A/SCompletedHormone-refractory Prostate CancerDenmark
-
British Columbia Cancer AgencyCompletedHormone Refractory Prostate CancerCanada
-
Ascenta TherapeuticsCompletedHormone Refractory Prostate CancerUnited States
-
Poniard PharmaceuticalsUnknownHormone Refractory Prostate CancerRussian Federation
-
Korean Cancer Study GroupCompletedHormone Refractory Prostate CancerKorea, Republic of
-
Zealand University HospitalUniversity Hospital Schleswig-HolsteinUnknownHormone-refractory Prostate CancerDenmark, Germany
-
AgennixCompletedProstate Cancer | Hormone Refractory Prostate CancerUnited States, United Kingdom, France, Italy, Israel, Germany, Hungary, Argentina, Russian Federation, Belgium, Croatia, Netherlands, Peru, Poland, Spain
-
Veeda OncologyBayerTerminatedHormone Refractory Prostate CancerUnited States
-
Zhengzhou UniversityThe First Affiliated Hospital of Zhengzhou University; Xinyang Central Hospital and other collaboratorsUnknown
-
CytoVac A/SCompletedHormone-refractory Prostate CancerDenmark
-
University of FloridaCureVacTerminated
-
National University Hospital, SingaporeCompletedHormone-Refractory Prostate CancerSingapore
-
CytRxCompletedHormone Refractory Prostate CancerUnited States
-
Ascenta TherapeuticsCompletedHormone Refractory Prostate CancerUnited States, Russian Federation
-
Merrion Pharmaceuticals, LLCCompletedHormone-Refractory Prostate CancerUnited States, Estonia, Latvia
-
David M LubaroffUnited States Department of DefenseCompletedHormone Refractory Prostate CancerUnited States
-
Cliniques universitaires Saint-Luc- Université...SanofiCompletedMetastatic Prostate Cancer | Hormone Resistant Prostate CancerBelgium, Luxembourg
-
Novartis PharmaceuticalsTerminatedHormone Refractory Prostate CancerUnited States
-
CelgeneCompletedHormone Refractory Prostate CancerUnited States
-
Queen's Medical CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedHormone Refractory Prostate CancerUnited States
-
Spanish Oncology Genito-Urinary GroupCompleted
-
Daniel George, MDNovartis PharmaceuticalsCompletedHormone Refractory Prostate CancerUnited States
-
DendreonCompletedHormone-Refractory Prostate Cancer
-
Medical University of ViennaUnknownHormone Refractory Prostate CancerAustria
-
Sheba Medical CenterUnknownHormone Refractory Prostate CancerIsrael
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)TerminatedMetastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate CancerUnited States
-
German Cancer Research CenterUniversity Hospital Freiburg; ABX CRO; Friedrich-Alexander-Universität Erlangen-NürnbergCompletedProstate Cancer | Prostate Cancer Metastatic | High-risk Prostate Cancer | Lymphnode MetastasisAustria, Germany
-
National Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Hormone Refractory Prostate CancerUnited States, Canada
-
National Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Hormone-refractory Prostate CancerUnited States
-
Novartis PharmaceuticalsTerminatedHormone Refractory Prostate Cancer DiseaseUnited States
-
Stanford UniversityNational Cancer Institute (NCI)TerminatedMetastatic Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Hormone-Resistant Prostate CancerUnited States